Advertisement
Screener

INOVIO PHARMACEUTICALS, INC. (INO) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

INOVIO PHARMACEUTICALS, INC. Research and Development Expense

INOVIO PHARMACEUTICALS, INC. (INO) reported Research and Development Expense of $10.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12

  • INOVIO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $10.83M, a 25.44% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $14.07M, a 12.56% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $10.26M, a 20.37% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $13.33M, a 28.83% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $54.21M, a 28.32% decline from fiscal 2024.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $75.62M, a 12.76% decline from fiscal 2023.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $86.68M, a 53.81% decline from fiscal 2022.
  • INOVIO PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $187.65M, a 24.71% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2026-06-30$10.83M
10-Q · filed 2026-08-12
$24.90M
10-Q · filed 2026-08-12
$35.16M
derived: sum of 3 quarters · filed 2026-08-12
$48.49M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$14.07M
10-Q · filed 2026-05-13
$24.33M
derived: sum of 2 quarters · filed 2026-05-13
$37.66M
derived: sum of 3 quarters · filed 2026-05-13
$52.19M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$10.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$23.59M
derived: sum of 2 quarters · filed 2026-03-12
$38.12M
derived: sum of 3 quarters · filed 2026-08-12
$54.21M
10-K · filed 2026-03-12
2025-09-30$13.33M
10-Q · filed 2025-11-10
$27.85M
derived: sum of 2 quarters · filed 2026-08-12
$43.95M
10-Q · filed 2025-11-10
$56.83M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$14.52M
10-Q · filed 2026-08-12
$30.61M
10-Q · filed 2026-08-12
$43.50M
derived: sum of 3 quarters · filed 2026-08-12
$62.23M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$16.09M
10-Q · filed 2026-05-13
$28.98M
derived: sum of 2 quarters · filed 2026-05-13
$47.71M
derived: sum of 3 quarters · filed 2026-05-13
$70.80M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$12.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$31.62M
derived: sum of 2 quarters · filed 2026-03-12
$54.71M
derived: sum of 3 quarters · filed 2026-03-12
$75.62M
10-K · filed 2026-03-12
2024-09-30$18.73M
10-Q · filed 2025-11-10
$41.82M
derived: sum of 2 quarters · filed 2025-11-10
$62.73M
10-Q · filed 2025-11-10
$79.99M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$23.09M
10-Q · filed 2025-08-12
$44.00M
10-Q · filed 2025-08-12
$61.26M
derived: sum of 3 quarters · filed 2025-08-12
$76.76M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$20.91M
10-Q · filed 2025-05-13
$38.17M
derived: sum of 2 quarters · filed 2025-05-13
$53.67M
derived: sum of 3 quarters · filed 2025-05-13
$77.41M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$17.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18
$32.76M
derived: sum of 2 quarters · filed 2025-03-18
$56.50M
derived: sum of 3 quarters · filed 2025-03-18
$86.68M
10-K · filed 2025-03-18
2023-09-30$15.50M
10-Q · filed 2024-11-14
$39.25M
derived: sum of 2 quarters · filed 2024-11-14
$69.42M
10-Q · filed 2024-11-14
$111.54M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$23.74M
10-Q · filed 2024-08-08
$53.92M
10-Q · filed 2024-08-08
$96.04M
derived: sum of 3 quarters · filed 2024-08-08
$129.13M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$30.18M
10-Q · filed 2024-05-13
$72.30M
derived: sum of 2 quarters · filed 2024-05-13
$105.38M
derived: sum of 3 quarters · filed 2024-05-13
$161.85M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$42.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
$75.21M
derived: sum of 2 quarters · filed 2024-03-06
$131.67M
derived: sum of 3 quarters · filed 2024-03-06
$187.65M
10-K · filed 2024-03-06
2022-09-30$33.09M
10-Q · filed 2023-11-09
$89.55M
derived: sum of 2 quarters · filed 2023-11-09
$145.53M
10-Q · filed 2023-11-09
$237.83M
derived: sum of 4 quarters · filed 2024-03-06
2022-06-30$56.46M
10-Q · filed 2023-08-09
$112.44M
10-Q · filed 2023-08-09
$204.74M
derived: sum of 3 quarters · filed 2024-03-06
$251.83M
derived: sum of 4 quarters · filed 2024-03-06
2022-03-31$55.98M
10-Q · filed 2023-05-10
$148.28M
derived: sum of 2 quarters · filed 2024-03-06
$195.37M
derived: sum of 3 quarters · filed 2024-03-06
$266.17M
derived: sum of 4 quarters · filed 2024-03-06
2021-12-31$92.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
$139.39M
derived: sum of 2 quarters · filed 2024-03-06
$210.20M
derived: sum of 3 quarters · filed 2024-03-06
$249.24M
10-K · filed 2024-03-06
2021-09-30$47.09M
10-Q · filed 2022-11-08
$117.90M
derived: sum of 2 quarters · filed 2022-11-08
$156.94M
10-Q · filed 2022-11-08
$183.24M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$70.81M
10-Q · filed 2022-08-09
$109.85M
10-Q · filed 2022-08-09
$136.16M
derived: sum of 3 quarters · filed 2022-08-09
$162.61M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$39.04M
10-Q · filed 2022-05-10
$65.35M
derived: sum of 2 quarters · filed 2022-05-10
$91.80M
derived: sum of 3 quarters · filed 2022-05-10
$114.18M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31$26.30M
10-K · filed 2021-03-01
$52.76M
derived: sum of 2 quarters · filed 2021-11-09
$75.13M
derived: sum of 3 quarters · filed 2021-11-09
$94.25M
10-K · filed 2023-03-01
2020-09-30$26.46M
10-Q · filed 2021-11-09
$48.83M
derived: sum of 2 quarters · filed 2021-11-09
$67.94M
10-Q · filed 2021-11-09
$89.95M
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30$22.38M
10-Q · filed 2021-08-09
$41.49M
10-Q · filed 2021-08-09
$63.49M
derived: sum of 3 quarters · filed 2021-08-09
$82.63M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$19.11M
10-Q · filed 2021-05-10
$41.12M
derived: sum of 2 quarters · filed 2021-05-10
$60.25M
derived: sum of 3 quarters · filed 2021-05-10
$82.74M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31$22.00M
10-K · filed 2021-03-01
$41.14M
derived: sum of 2 quarters · filed 2021-03-01
$63.63M
derived: sum of 3 quarters · filed 2021-03-01
$88.02M
10-K · filed 2022-03-01
2019-09-30$19.14M
10-K · filed 2021-03-01
$41.62M
derived: sum of 2 quarters · filed 2021-03-01
$66.01M
10-Q · filed 2020-11-09
$92.38M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$22.49M
10-K · filed 2021-03-01
$46.88M
10-Q · filed 2020-08-10
$73.24M
derived: sum of 3 quarters · filed 2021-03-01
$95.09M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$24.39M
10-K · filed 2021-03-01
$50.76M
derived: sum of 2 quarters · filed 2021-03-01
$72.61M
derived: sum of 3 quarters · filed 2021-03-01
$95.07M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$26.37M
10-K · filed 2020-03-12
$48.22M
derived: sum of 2 quarters · filed 2020-03-12
$70.68M
derived: sum of 3 quarters · filed 2020-03-12
$95.26M
10-K · filed 2021-03-01
2018-09-30$21.85M
10-K · filed 2020-03-12
$44.31M
derived: sum of 2 quarters · filed 2020-03-12
$68.89M
10-Q · filed 2019-11-12
$93.53M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$22.46M
10-K · filed 2020-03-12
$47.04M
10-Q · filed 2019-08-08
$71.68M
derived: sum of 3 quarters · filed 2020-03-12
$97.19M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$24.58M
10-K · filed 2020-03-12
$49.22M
derived: sum of 2 quarters · filed 2020-03-12
$74.73M
derived: sum of 3 quarters · filed 2020-03-12
$98.61M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$24.64M
10-K · filed 2019-03-12
$50.15M
derived: sum of 2 quarters · filed 2019-03-12
$74.03M
derived: sum of 3 quarters · filed 2019-03-12
$98.57M
10-K · filed 2020-03-12
2017-09-30$25.51M
10-K · filed 2019-03-12
$49.39M
derived: sum of 2 quarters · filed 2019-03-12
$73.93M
10-Q · filed 2018-11-08
$97.84M
derived: sum of 4 quarters · filed 2019-03-12
2017-06-30$23.88M
10-K · filed 2019-03-12
$48.42M
10-Q · filed 2018-08-07
$72.33M
derived: sum of 3 quarters · filed 2019-03-12
$99.31M
derived: sum of 4 quarters · filed 2019-03-12
2017-03-31$24.54M
10-K · filed 2019-03-12
$48.45M
derived: sum of 2 quarters · filed 2019-03-12
$75.43M
derived: sum of 3 quarters · filed 2019-03-12
$95.07M
derived: sum of 4 quarters · filed 2019-03-12
2016-12-31$23.91M
10-K · filed 2018-03-14
$50.89M
derived: sum of 2 quarters · filed 2018-03-14
$70.52M
derived: sum of 3 quarters · filed 2018-03-14
$88.71M
10-K · filed 2019-03-12
2016-09-30$26.98M
10-K · filed 2018-03-14
$46.61M
derived: sum of 2 quarters · filed 2018-03-14
$64.80M
10-Q · filed 2017-11-08
$80.40M
derived: sum of 4 quarters · filed 2018-03-14
2016-06-30$19.63M
10-K · filed 2018-03-14
$37.82M
10-Q · filed 2017-08-08
$53.42M
derived: sum of 3 quarters · filed 2018-03-14
$69.50M
derived: sum of 4 quarters · filed 2018-03-14
2016-03-31$18.19M
10-K · filed 2018-03-14
$33.79M
derived: sum of 2 quarters · filed 2018-03-14
$49.87M
derived: sum of 3 quarters · filed 2018-03-14
$66.55M
derived: sum of 4 quarters · filed 2018-03-14
2015-12-31$15.60M
10-K · filed 2017-03-15
$31.68M
derived: sum of 2 quarters · filed 2017-03-15
$48.37M
derived: sum of 3 quarters · filed 2017-03-15
$57.79M
10-K · filed 2018-03-14
2015-09-30$16.08M
10-K · filed 2017-03-15
$32.76M
derived: sum of 2 quarters · filed 2017-03-15
$42.19M
10-Q · filed 2016-11-09
$51.43M
derived: sum of 4 quarters · filed 2017-03-15
2015-06-30$16.69M
10-K · filed 2017-03-15
$26.11M
10-Q · filed 2016-08-08
$35.36M
derived: sum of 3 quarters · filed 2017-03-15
$42.38M
derived: sum of 4 quarters · filed 2017-03-15
2015-03-31$9.43M
10-K · filed 2017-03-15
$18.67M
derived: sum of 2 quarters · filed 2017-03-15
$25.69M
derived: sum of 3 quarters · filed 2017-03-15
$35.30M
derived: sum of 4 quarters · filed 2017-03-15
2014-12-31$9.24M
10-K · filed 2016-03-14
$16.26M
derived: sum of 2 quarters · filed 2016-03-14
$25.87M
derived: sum of 3 quarters · filed 2016-03-14
$34.10M
10-K · filed 2017-03-15
2014-09-30$7.02M
10-K · filed 2016-03-14
$16.63M
derived: sum of 2 quarters · filed 2016-03-14
$24.85M
10-Q · filed 2015-11-09
$31.25M
derived: sum of 4 quarters · filed 2016-03-14
2014-06-30$9.61M
10-K · filed 2016-03-14
$17.83M
10-Q · filed 2015-08-10
$24.24M
derived: sum of 3 quarters · filed 2016-03-14
$29.68M
derived: sum of 4 quarters · filed 2016-03-14
2014-03-31$8.23M
10-K · filed 2016-03-14
$14.63M
derived: sum of 2 quarters · filed 2016-03-14
$20.07M
derived: sum of 3 quarters · filed 2016-03-14
$24.48M
derived: sum of 4 quarters · filed 2016-03-14
2013-12-31$6.40M
10-K · filed 2015-03-16
$11.84M
derived: sum of 2 quarters · filed 2015-03-16
$16.25M
derived: sum of 3 quarters · filed 2015-03-16
$21.37M
10-K · filed 2016-03-14
2013-09-30$5.44M
10-K · filed 2015-03-16
$9.85M
derived: sum of 2 quarters · filed 2015-03-16
$14.96M
10-Q · filed 2014-11-10
$19.41M
derived: sum of 4 quarters · filed 2015-03-16
2013-06-30$4.41M
10-K · filed 2015-03-16
$9.53M
10-Q · filed 2014-08-11
$13.97M
derived: sum of 3 quarters · filed 2015-03-16
$18.94M
derived: sum of 4 quarters · filed 2015-03-16
2013-03-31$5.12M
10-K · filed 2015-03-16
$9.56M
derived: sum of 2 quarters · filed 2015-03-16
$14.53M
derived: sum of 3 quarters · filed 2015-03-16
$19.06M
derived: sum of 4 quarters · filed 2015-03-16
2012-12-31$4.44M
10-K · filed 2014-03-17
$9.42M
derived: sum of 2 quarters · filed 2014-03-17
$13.94M
derived: sum of 3 quarters · filed 2014-03-17
$17.98M
10-K · filed 2015-03-16
2012-09-30$4.97M
10-K · filed 2014-03-17
$9.50M
derived: sum of 2 quarters · filed 2014-03-17
$13.54M
10-Q · filed 2013-11-12
$17.70M
derived: sum of 4 quarters · filed 2014-03-17
2012-06-30$4.53M
10-K · filed 2014-03-17
$8.57M
10-Q · filed 2013-08-09
$12.73M
derived: sum of 3 quarters · filed 2014-03-17
$19.72M
derived: sum of 4 quarters · filed 2014-03-17
2012-03-31$4.04M
10-K · filed 2014-03-17
$8.20M
derived: sum of 2 quarters · filed 2014-03-17
$15.19M
derived: sum of 3 quarters · filed 2014-03-17
$19.65M
derived: sum of 4 quarters · filed 2014-03-17
2011-12-31$4.16M
10-K · filed 2013-03-18
$11.15M
derived: sum of 2 quarters · filed 2013-03-18
$15.61M
derived: sum of 3 quarters · filed 2013-03-18
$20.03M
10-K · filed 2014-03-17
2011-09-30$6.99M
10-K · filed 2013-03-18
$11.45M
derived: sum of 2 quarters · filed 2013-03-18
$15.87M
10-Q · filed 2012-11-07
$20.37M
derived: sum of 4 quarters · filed 2013-03-18
2011-06-30$4.46M
10-K · filed 2013-03-18
$8.89M
10-Q · filed 2012-08-09
$13.38M
derived: sum of 3 quarters · filed 2013-03-18
$16.33M
derived: sum of 4 quarters · filed 2013-03-18
2011-03-31$4.42M
10-K · filed 2013-03-18
$8.91M
derived: sum of 2 quarters · filed 2013-03-18
$11.86M
derived: sum of 3 quarters · filed 2013-03-18
$14.95M
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$4.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$7.44M
derived: sum of 2 quarters · filed 2013-03-18
$10.53M
derived: sum of 3 quarters · filed 2013-03-18
$13.26M
10-K · filed 2013-03-18
2010-09-30$2.95M
10-Q · filed 2011-11-07
$6.03M
derived: sum of 2 quarters · filed 2011-11-07
$8.76M
10-Q · filed 2011-11-07
2010-06-30$3.08M
10-Q · filed 2011-08-05
$5.81M
10-Q · filed 2011-08-05
2009-12-31$9.41M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
MEDICINOVA INC (MNOV)United States$0.130B-6.04
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Immuneering Corp (IMRX)United States$0.113B-12.51